Ductal adenocarcinoma of pancreas – Diagnostics – Overview of Information and Clinical Research

Diagnosing ductal adenocarcinoma of the pancreas is one of the most challenging aspects of managing this disease, as it often remains silent in its early stages when treatment could be most effective. Understanding when to seek diagnostic testing, what methods are used, and how these tests support clinical trial participation is crucial for patients and their loved ones navigating this difficult journey.

Introduction: Who Should Undergo Diagnostics and When

Pancreatic ductal adenocarcinoma, often simply called PDAC, is a particularly difficult disease to catch early because it typically doesn’t cause noticeable symptoms until it has already grown or spread to other parts of the body^[1]. This makes knowing when to seek diagnostic testing especially important. Unfortunately, most people with this type of cancer don’t feel anything wrong during the disease’s early stages, which is why symptoms specific enough to suggest pancreatic cancer usually don’t appear until the disease is more advanced^[11].

People who should consider diagnostic testing include those experiencing certain warning signs or those at higher risk for developing pancreatic cancer. The most common symptoms that should prompt you to see a doctor include yellowing of the skin or the whites of the eyes, which doctors call jaundice^[8]. This happens when a tumor blocks the bile duct. Other concerning signs include persistent pain in the upper part of the belly or in the middle of the back, unexplained weight loss without trying, light-colored bowel movements, dark urine, and ongoing fatigue^[5]^[7].

Your doctor might also suspect pancreatic cancer if you’ve recently developed diabetes for the first time, especially if you’re older, or if you have a sudden inflammation of the pancreas called pancreatitis without an obvious cause^[8]. Some people report feeling generally unwell, with symptoms like nausea, vomiting, bloating, or loss of appetite^[8]. Because these symptoms can be vague and might suggest other, less serious conditions, many people and their doctors don’t immediately think of pancreatic cancer, which contributes to delayed diagnosis.

⚠️ Important

Anyone with a family history of pancreatic cancer or certain genetic conditions should talk to their doctor about screening, even without symptoms. If you have chronic pancreatitis, a history of smoking, obesity, or type 2 diabetes, you’re also at increased risk and should remain alert to any unusual changes in your health^[11].

Certain groups of people are at higher risk and should be especially vigilant. Risk factors include having a family history of pancreatic cancer, carrying genetic mutations such as those in the BRCA1 or BRCA2 genes (which are also linked to breast and ovarian cancer), or having inherited conditions like Lynch syndrome^[11]. Lifestyle factors matter too. Smoking cigarettes is one of the most significant risk factors, roughly doubling your chances of developing this cancer^[12]. Being overweight, having chronic inflammation of the pancreas, and even certain dietary patterns can also increase risk^[1].

If you fall into any of these higher-risk categories or experience any of the symptoms mentioned, it’s important to contact a doctor promptly. Regular checkups can sometimes reveal subtle signs on blood tests or during a physical examination, even before you notice anything unusual yourself^[5]. Early detection is rare with pancreatic cancer, but when it happens, it offers the best chance for successful treatment.

Diagnostic Methods Used to Identify the Disease

When a doctor suspects pancreatic cancer based on symptoms or risk factors, several diagnostic tests can help confirm the diagnosis and determine how far the disease has spread. Because pancreatic tumors are located deep inside the body, hidden behind the stomach and surrounded by other organs like the liver and small intestine, special imaging and testing methods are needed^[7].

Physical Examination and Medical History

Your doctor will begin with a thorough physical examination and ask detailed questions about your symptoms, medical history, lifestyle habits like smoking or alcohol use, and any family history of cancer. During the physical exam, the doctor may feel your abdomen for any unusual lumps or swelling, check for an enlarged gallbladder, and look for signs of jaundice^[8]. While a physical exam alone cannot diagnose pancreatic cancer, it provides important clues.

Blood Tests

Blood tests play a supporting role in diagnosing pancreatic cancer. Your doctor may check your liver function through blood work, which can show abnormal results if a tumor is blocking your bile ducts. Blood tests can also detect elevated levels of certain substances, though these aren’t specific enough on their own to confirm cancer^[10]. Sometimes, changes in blood sugar levels or new-onset diabetes detected through blood testing can be an early warning sign^[8].

Imaging Tests

Imaging is the most important tool for detecting and evaluating pancreatic cancer. Several different types of imaging tests are commonly used, each offering different information:

Computed tomography, or CT scan, is often the first imaging test ordered when pancreatic cancer is suspected. This test uses X-rays taken from many angles to create detailed cross-sectional images of your pancreas and surrounding organs^[10]. A CT scan can show the size and location of a tumor, whether it has spread to nearby blood vessels, and if it has reached other organs like the liver or lungs. You may need to drink a contrast liquid or receive an injection of contrast dye before the scan to make the images clearer.

Magnetic resonance imaging, or MRI, uses powerful magnets and radio waves instead of X-rays to create detailed pictures of your internal organs. MRI is particularly good at showing soft tissues and can help doctors see the pancreas and surrounding structures in great detail^[10]. It’s especially useful for evaluating whether a tumor can be surgically removed.

Ultrasound uses sound waves to create images of organs inside your body. While a regular abdominal ultrasound can sometimes detect pancreatic tumors, a specialized type called endoscopic ultrasound (EUS) is often more helpful. During an EUS, a thin, flexible tube with an ultrasound probe on the end is passed down your throat and into your stomach and small intestine, allowing the doctor to get very close to your pancreas for detailed images^[10]. This test can also guide a needle biopsy if needed.

Positron emission tomography, or PET scan, involves injecting a small amount of radioactive sugar into your bloodstream. Cancer cells, which use more sugar than normal cells, show up as bright spots on the scan. PET scans are sometimes combined with CT scans to provide both anatomical and functional information, helping to detect cancer that has spread to distant parts of the body^[10].

Endoscopic Procedures

Several procedures use a thin, flexible tube with a camera (called an endoscope) to look inside your digestive system and pancreatic ducts. Endoscopic retrograde cholangiopancreatography, or ERCP, involves passing an endoscope through your mouth, down your esophagus and stomach, and into the first part of your small intestine where the bile and pancreatic ducts open^[10]. The doctor can inject dye into these ducts and take X-rays to look for blockages caused by tumors. ERCP can also be used to place a small tube called a stent to relieve a blocked bile duct and reduce jaundice.

Tissue Biopsy

A biopsy involves removing a small sample of tissue from the suspicious area so it can be examined under a microscope. This is the only way to definitively confirm that cancer is present and determine exactly what type it is. Biopsies of the pancreas can be done in several ways. The most common method is a needle biopsy guided by endoscopic ultrasound or CT scan, where a thin needle is inserted through the skin or through the wall of the stomach or intestine to reach the tumor^[10]. Sometimes, if surgery is already planned, the biopsy might be done during the operation itself.

Staging the Disease

Once pancreatic cancer is diagnosed, doctors need to determine the stage of the disease, meaning how large the tumor is and whether it has spread. This information is critical for deciding on the best treatment approach. Staging typically involves combining information from all the imaging tests mentioned above. Doctors classify pancreatic cancer into several categories: resectable (can be removed with surgery), borderline resectable (might be removable with surgery), locally advanced (has grown into nearby blood vessels or tissues but hasn’t spread far away), or metastatic (has spread to distant organs)^[11]^[6].

⚠️ Important

Because early-stage pancreatic tumors don’t show up well on imaging tests, many people don’t receive a diagnosis until the cancer has already spread. This is why the disease is often found at an advanced stage, making treatment more challenging^[8]. Ongoing research is focused on finding better ways to detect pancreatic cancer earlier.

Diagnostics for Clinical Trial Qualification

Clinical trials are research studies that test new treatments or combinations of treatments to see if they work better than current standard approaches. For patients with pancreatic ductal adenocarcinoma, participating in a clinical trial may offer access to promising new therapies that aren’t yet widely available. However, to join a clinical trial, patients must meet specific eligibility criteria, which require certain diagnostic tests and assessments.

Confirming the Diagnosis

Before you can enroll in any clinical trial for pancreatic cancer, you need a confirmed diagnosis of ductal adenocarcinoma, typically through a biopsy that shows cancer cells under the microscope. The pathology report from your biopsy will specify the exact type of cancer you have, which is important because clinical trials are usually designed for specific cancer types^[10].

Tumor Staging and Imaging

Clinical trials often have strict requirements about what stage of cancer they will accept. Some trials are only for people with metastatic disease (cancer that has spread to other organs), while others focus on earlier stages that might be treatable with surgery. You’ll need recent imaging studies, such as CT scans, MRI, or PET scans, to document the size and location of your tumor and whether the cancer has spread^[10]. These imaging tests must usually be done within a few weeks before you enroll in a trial.

Genetic and Biomarker Testing

Modern clinical trials increasingly focus on the genetic and molecular characteristics of tumors. Researchers have found that certain genetic changes in pancreatic cancer cells can predict which treatments might work best. For example, studies have shown that mutations in a gene called KRAS are present in about 93 percent of pancreatic cancers^[4]. Other genetic changes involving genes like BRCA1, BRCA2, ATM, and others can also be important for treatment decisions.

Many clinical trials now require what’s called genetic testing or biomarker testing of your tumor tissue. This involves analyzing the DNA from your biopsy sample to look for specific mutations or other molecular features. This testing helps match you to trials studying treatments that target those specific genetic changes. Some trials look at the tumor’s genetic signature to identify subtypes of pancreatic cancer that might respond differently to certain drugs^[4].

Blood Tests and Organ Function

Before joining a clinical trial, you’ll typically need a comprehensive set of blood tests to assess your overall health and make sure your organs are functioning well enough to tolerate the experimental treatment. These tests usually include a complete blood count to check your red and white blood cells and platelets, liver function tests, kidney function tests, and tests to check your blood sugar and electrolyte levels^[11]. Clinical trials have specific requirements for these values, and you may not be eligible if certain tests are too far outside the normal range.

Performance Status Assessment

Clinical trials also assess your general physical condition and ability to carry out daily activities, which doctors call your performance status. This is usually measured using a simple scale that rates your level of functioning from fully active to completely bedridden. Trials often require that patients have a good performance status, meaning they can take care of themselves and are up and moving around at least half their waking hours^[6]. Your doctor will evaluate this as part of determining your eligibility.

Additional Testing Requirements

Depending on the specific trial, you might need additional specialized tests. Some trials require heart function tests like an electrocardiogram or echocardiogram, especially if the treatment being studied could affect the heart. Others might need tests of your lung function. If you’ve had previous cancer treatments, the trial may require documentation of what treatments you received and how well they worked.

It’s important to understand that meeting all the diagnostic criteria for a clinical trial doesn’t guarantee you’ll be accepted. Trials have limited spaces, and sometimes many patients apply for the same study. However, having all the required diagnostic information ready can speed up the screening process and increase your chances of enrolling if a spot becomes available.

Prognosis and Survival Rate

Prognosis

The outlook for patients with ductal adenocarcinoma of the pancreas depends heavily on several factors, particularly the stage at which the cancer is detected and whether it can be surgically removed. Unfortunately, because early symptoms are often absent or vague, most people are diagnosed when the disease has already spread, which significantly affects their prognosis^[1]. Only about 10 to 20 percent of patients have cancer that can be surgically removed at the time of diagnosis, and these patients generally have the best chance of longer-term survival^[6]^[7]. Even among those who undergo successful surgery, the cancer returns in about 75 percent of cases^[17].

Several factors influence prognosis beyond just the stage of disease. These include the size and location of the tumor, whether it has grown into nearby blood vessels, the patient’s overall health and ability to tolerate treatment, and increasingly, the genetic characteristics of the tumor itself. Research has shown that certain genetic patterns, such as mutations in KRAS and other genes in related pathways, are common in pancreatic cancer and can affect how the disease behaves^[4]. Some patients may have genetic changes that make their tumors more responsive to specific treatments, which can improve their outlook.

The disease stage matters tremendously. Patients with cancer that hasn’t spread beyond the pancreas have a better prognosis than those whose cancer has reached distant organs like the liver or lungs. For those with metastatic disease, meaning the cancer has spread far from the pancreas, treatment focuses on controlling symptoms, slowing the disease’s progression, and maintaining quality of life rather than attempting a cure^[6]^[7].

It’s worth noting that prognosis is constantly improving as new treatments become available. Combination chemotherapy regimens and newer targeted therapies have shown promise in extending survival times for some patients. Research findings indicate that about 42 percent of pancreatic tumors studied had genetic changes that might qualify patients for current clinical trials, offering hope that more personalized treatment approaches will continue to improve outcomes^[4].

Survival Rate

Pancreatic ductal adenocarcinoma has historically had one of the lowest survival rates among all cancer types. The overall five-year survival rate, meaning the percentage of patients who are still alive five years after diagnosis, is approximately 8 percent across all stages combined^[5]^[6]. This low number reflects the fact that most patients are diagnosed at advanced stages when the cancer has already spread.

However, these statistics vary significantly depending on the stage at diagnosis. Patients whose cancer is found early and can be completely removed with surgery, followed by additional treatments, have notably better survival rates than those diagnosed with metastatic disease. The challenge is that early detection remains rare due to the lack of specific symptoms in the beginning stages of the disease^[5].

Pancreatic cancer is currently the fourth most common cause of cancer-related deaths worldwide, and projections suggest it may become the second leading cause of cancer deaths in the United States by 2030^[6]^[8]. The incidence of pancreatic cancer is rising, likely due to factors including an aging population and increasing rates of obesity and type 2 diabetes, both of which are known risk factors for developing this disease^[6].

Despite these sobering statistics, it’s important to remember that survival rates are based on large groups of people and may not predict what will happen in any individual case. Each patient’s situation is unique, and factors like overall health, response to treatment, and access to specialized care all play important roles. Furthermore, survival statistics are constantly changing as new treatments emerge and researchers learn more about this disease. Organizations and research initiatives are working toward a goal of increasing the five-year survival rate from the current 12 percent to 50 percent within the next decade through advances in early detection and more effective treatments^[17].

#1 Clinical Trials Search in Europe

Ductal adenocarcinoma of pancreas – Diagnostics

Introduction: Who Should Undergo Diagnostics and When